AllMeD Solutions, which holds the Israeli biomedical company TruLeaf-Medical, announced the successful completion of stage 1 of the first human implantation of the innovative RoseDoc docking system for transcatheter replacement of the tricuspidvalve. This is a breakthrough system that replaces diseased heart valves and is inserted via catheter, without the need for open-heart surgery.

The procedure was successfully performed for the first time on September 5th, 2025, in India, using a compassionate care pathway, on two patients suffering from severe refractory congestive heart failure due to a leaking tricuspid valve who had no alternative therapeutic options. The second phase of percutaneously (using needle stick only) implanting the implantation of valve itself, developed by the company withing the docking device, is expected to be performed in the coming months according to the trial protocol. The current step represents a major proof of concept in humans for TruLeaf innovative technology aimed at transcatheter replacement of the mitral and tricuspid valves.